Tiblio
Sign Up

MNOV

MediciNova Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$65.46M
P/E Ratio
—
EPS
$-0.23
Beta
0.62
52W High
$1.96
52W Low
$1.17
50-Day MA
$1.35
200-Day MA
$1.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.53
PEG Ratio
-0.94

About MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapies for the treatment of serious diseases with unmet medical needs in the United States. The company is headquartered in La Jolla, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)596,640
Gross Profit (TTM)47,930
EBITDA$-12.90M
Operating Margin-1517.00%
Return on Equity-26.20%
Return on Assets-17.00%
Revenue/Share (TTM)$0.01
Book Value$0.80
Price-to-Book1.65
Price-to-Sales (TTM)109.72
EV/Revenue63.37
EV/EBITDA-2.65
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$49.22M
Float$42.26M
% Insiders2.88%
% Institutions11.05%

Historical Volatility

HV 10-Day
31.72%
HV 20-Day
37.74%
HV 30-Day
38.27%
HV 60-Day
33.32%
HV Rank
31.0%

Volatility is currently contracting

Analyst Ratings

Consensus ($9.00 target)
1
Strong Buy
2
Buy

Latest News

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS ; NCT 06743776) evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS).

GlobeNewsWire7/15/2026Neutral
MediciNova CEO Provides Shareholder Update

LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D.

GlobeNewsWire6/30/2026Neutral
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM).

GlobeNewsWire5/26/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MNOV and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncUNHUnitedHealth Group IncorporatedMRKMerck & Company IncNVSNovartis AG ADRAZNAstraZeneca PLCNVONovo Nordisk A/STMOThermo Fisher Scientific IncAMGNAmgen IncABTAbbott LaboratoriesGILDGilead Sciences Inc
View all HEALTHCARE stocks →
Data last updated: 7/29/2026